Oral anticoagulants in patients with coronary artery disease
Sonia S. Anand, MD, MSc, FRCP(C)*,* and
Salim Yusuf, FRCP, Dphil*
* Department of Medicine, Division of Cardiology and Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
View larger version (27K):
[in a new window]
|
Figure 1 High intensity oral anticoagulation versus control. Outcomes are cardiovascular death, myocardial infarction, or stroke. ASPECT = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis; CI = confidence interval; df = degrees of freedom; N = study population; n = subset population; OA = oral anticoagulation; OR = odds ratio; WARIS = Warfarin-Aspirin ReInfarction Study.
|
|
View larger version (12K):
[in a new window]
|
Figure 2 Major bleeding rates in patients with vascular disease. A = aspirin; C = control; INR = international normalized ratio; N = study population; n = subset population; OA = oral anticoagulation. (Adapted from Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058–67. Copyrighted 2002, American Medical Association.)
|
|
View larger version (15K):
[in a new window]
|
Figure 3 Moderate intensity oral anticoagulation versus control. Outcomes are cardiovascular death, myocardial infarction, or stroke. CI = confidence interval; COOP = Veterans Administration COOPerative study; df = degrees of freedom; OA = oral anticoagulation; N = study population; n = subset population; OR = odds ratio.
|
|
View larger version (18K):
[in a new window]
|
Figure 4 Moderate-to-high-intensity oral anticoagulation versus aspirin. Outcomes are cardiovascular death, myocardial infarction, or stroke. ASPECT = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis; ATACS = Antithrombotic Therapy in Acute Coronary Syndrome; CI = confidence interval; df = degrees of freedom; EPSIM = Enquete de Prevention Secondaire de I’Infarctus du Myocarde; N = study population; n = subset population; OR = odds ratio; WARIS = Warfarin-Aspirin ReInfarction Study.
|
|
View larger version (19K):
[in a new window]
|
Figure 5 Moderate-to-high-intensity oral anticoagulation plus aspirin versus aspirin alone. Outcomes are cardiovascular death, myocardial infarction, or stroke. ASPECT = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis; ATACS = Antithrombotic Therapy in Acute Coronary Syndrome; CHAMP = Combination Hemotherapy And Mortality Prevention; CI = confidence interval; df = degrees of freedom; OA = oral anticoagulation; OASIS = Organization to Assess Strategies for Ischemic Syndromes; OR = odds ratio; WARIS = Warfarin-Aspirin ReInfarction Study.
|
|
View larger version (14K):
[in a new window]
|
Figure 6 Moderate intensity oral anticoagulation plus aspirin versus moderate-to-high-intensity oral anticoagulation. Outcomes are cardiovascular death, myocardial infarction, or stroke. ASPECT = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis; ATACS = Antithrombotic Therapy in Acute Coronary Syndrome; CI = confidence interval; df = degrees of freedom; OA = oral anticoagulation; OR = odds ratio; WARIS = Warfarin-Aspirin ReInfarction Study.
|
|
View larger version (14K):
[in a new window]
|
Figure 7 Low intensity oral anticoagulation plus aspirin versus aspirin alone. Outcomes are cardiovascular death, myocardial infarction, or stroke. CABG = coronary artery bypass graft; CARS = Coumadin Aspirin Reinfarction Study; CI = confidence interval; df = degrees of freedom; N = study population; n = subset population; OA = oral anticoagulation; OASIS = Organization to Assess Strategies for Ischemic Syndrome; OR = odds ratio.
|
|
|
